Partnership Opportunities

Looking to Position Yourself as a Leader in the Gene Editing Field?

As the only event uniting analytical development drug developers in the gene editing field, this is your opportunity to establish brand excellence and forge relationships with decision makers from both established large companies, and new entrants to the field.

More and more companies are entering the space and require tried and trusted expertise to outsource to, and source provisions from, with our audience telling us they seek expert solutions in the following analytical domains:

Instrument Providers

Highly sensitive and specific analytical instruments (e.g., PCR, LC-MS)


Widely applicable sequencing platforms (e.g. Sanger sequencing, NGS)

Assay Providers

Validated nonclinical, clinical, and CMC assays and bioassays

In return, we can provide you with a unique platform to showcase your capabilities, helping you establish a new network of potential clients and establish an edge over your competitors.

If you work to support gene editing analytical development figures and are looking to establish yourself as a market leader, this is the one meeting in 2024 you need to partner with.

Get in touch to explore how we can position your brand in front of 25+ targeted companies.

Who Attended in 2023?

41667 - Companies Attending (2)

Audience Breakdown:

Audience Breakdown

*Estimated Attendance Based on CRISPR 2.0*

Editas Medicine - CRISPR-Based Therapy Analytical Development Summit

“As a first meeting, it really set up the tone for the future meetings, great to have a specific meeting for CRISPR analytical assays as we move these products from Research to Clinic”

Editas Medicine

“I really enjoyed the focus on assay development, HPLC and MS based method development, and challenges facing the industry around critical starting material characterization”

Vor Biopharma

Vor Biopharma - CRISPR-Based Therapy Analytical Development Summit
Recode Therapeutics - CRISPR-Based Therapy Analytical Development Summit

“The opportunity to network with peers in the field was great”

ReCode Therapeutics